NCT00297713View on ClinicalTrials.gov

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

June 30, 2006

Conditions
Adult Growth Hormone Deficiency
Interventions
DRUG

ALTU-238

Trial Locations (3)

40202

University of Louisville, Louisville

77555

University of Texas Medical Branch, Galveston

78229

Diabetes and Glandular Disease Clinic, San Antonio

Sponsors
All Listed Sponsors
lead

Altus Pharmaceuticals

INDUSTRY

NCT00297713 - Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety | Biotech Hunter | Biotech Hunter